Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,943 INR | +3.26% | -2.90% | +2.41% |
Feb. 29 | Cynata Therapeutics Names Chief Business Officer; Shares Plunge 14% | MT |
Feb. 28 | Glaxosmithkline Pharmaceuticals Limited Appoints Aparajita Mukherjee Rajput, Technology Lead | CI |
Sales 2024 * | 33.65B 404M | Sales 2025 * | 36.49B 438M | Capitalization | 329B 3.95B |
---|---|---|---|---|---|
Net income 2024 * | 6.06B 72.76M | Net income 2025 * | 7.68B 92.14M | EV / Sales 2024 * | 9.78 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 9.02 x |
P/E ratio 2024 * |
48.3
x | P/E ratio 2025 * |
42.9
x | Employees | 3,680 |
Yield 2024 * |
1.56% | Yield 2025 * |
1.62% | Free-Float | 24.42% |
Latest transcript on GlaxoSmithKline Pharmaceuticals Limited
1 day | +3.26% | ||
1 week | -2.90% | ||
Current month | -10.54% | ||
1 month | -10.45% | ||
3 months | +7.28% | ||
6 months | +27.37% | ||
Current year | +2.41% |
Managers | Title | Age | Since |
---|---|---|---|
Bhushan Akshikar
CEO | Chief Executive Officer | 54 | 22-11-30 |
Juby Chandy
DFI | Director of Finance/CFO | - | 22-03-31 |
Simrat Sohal
CMP | Compliance Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Renu Sud Karnad
CHM | Chairman | 70 | 19-03-31 |
Manu Anand
BRD | Director/Board Member | 64 | 22-05-15 |
Director/Board Member | 74 | 15-03-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 4 M€ | -4.41% | - | |
0.01% | 115 M€ | +4.98% | - | |
0.00% | 30 M€ | +5.34% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1,943 | +3.26% | 18 731 |
24-03-27 | 1,882 | -2.22% | 11,954 |
24-03-26 | 1,924 | -1.98% | 8,662 |
24-03-22 | 1,963 | -1.36% | 7,903 |
24-03-21 | 1,991 | -0.52% | 6,833 |
Delayed Quote Bombay S.E., March 28, 2024 at 06:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.41% | 3.83B | |
+34.99% | 701B | |
+26.24% | 571B | |
+1.10% | 381B | |
+20.83% | 334B | |
+17.04% | 319B | |
+0.74% | 210B | |
+2.95% | 210B | |
-6.05% | 201B | |
-2.62% | 157B |